Nasdaq · CIK 0001497253
VIVS VivoSim Labs, INC.
Insider trading from SEC Form 4. Last filing 42 d ago. Close $0.18 on Oct 9, 2026, 0% from the 52-week low and -95% from the high.
VivoSim Labs, INC. (VIVS) has 9 SEC Form 4 filings on file from 7 insiders, the latest filed on Sep 1, 2026. In the last 90 days insiders made 1 open-market buy worth $2,804 and 0 open-market sells worth $0, net +$2,804.
2 open-market trades have been scored at VIVS. The newest: Tony Serge Lialin (Chief Commercial Officer) bought $2,804 of stock on Aug 31, 2026, filed Sep 1, 2026, scored 23 (weak). The largest of the 2 shown: David Gobel (director) sold $7,300 on Nov 17, 2025, scored 35 (weak).
VIVS closed at $0.18 on Oct 9, 2026, 0% above its 52-week low and 95% below its 52-week high.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at VivoSim Labs, INC., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 23Weak | Tony Serge Lialin Chief Commercial Officer buy | $2,804 10,000 shares | - | - | |
| 35Weak | David Gobel director sell | $7,300 3,266 shares | -100% | +62% from low-85% from high |
Transactions
Every row filed, 9 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 31, 2026 | Tony Serge Lialin Chief Commercial Officer | POpen-market purchase Common Stock | +10,000 | $0.28 | $2,804 | 10,000 | 42 d ago |
| Jan 27, 2026 | Douglas Jay Cohen director | AGrant or award Common Stock | +15,000 | $0.00 | $0 | 20,732 | Jan 29, 2026 |
| Jan 27, 2026 | David Gobel director | AGrant or award Common Stock | +15,000 | $0.00 | $0 | 15,000 | Jan 29, 2026 |
| Jan 27, 2026 | Alison Tjosvold Milhous director | AGrant or award Common Stock | +15,000 | $0.00 | $0 | 19,899 | Jan 29, 2026 |
| Jan 27, 2026 | Keith Murphy EXECUTIVE CHAIRMAN | AGrant or award Common Stock | +15,000 | $0.00 | $0 | 26,053 | Jan 29, 2026 |
| Jan 27, 2026 | Adam K Stern director | AGrant or award Common Stock | +15,000 | $0.00 | $0 | 19,899 | Jan 29, 2026 |
| Nov 25, 2025 | Amar Akhtar Sethi Chief Scientific Officer | AGrant or award Options (right to buy)derivative | +53,500 | $0.00 | $0 | 53,500 | Nov 26, 2025 |
| Nov 17, 2025 | David Gobel director | SOpen-market sale Common Stock | +3,266 | $2.24 | $7,300 | 0 | Nov 19, 2025 |
| Aug 11, 2025 | Tony Serge Lialin Chief Commercial Officer | AGrant or award Options (right to buy)derivative | +40,000 | $0.00 | $0 | 40,000 | Aug 21, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Douglas Jay Cohendirector
- David Gobeldirector
- Tony Serge LialinChief Commercial Officer
- Alison Tjosvold Milhousdirector
- Keith MurphyEXECUTIVE CHAIRMAN
- Adam K Sterndirector
- Amar Akhtar SethiChief Scientific Officer
Questions about VIVS
Answered from the filings on this page, as of the latest one.
Are insiders buying VIVS?
As of Sep 1, 2026, SEC Form 4 filings show 1 open-market buy worth $2,804 by 1 insider and 0 open-market sells worth $0 by 0 insiders at VivoSim Labs, INC. in the last 90 days, net +$2,804. Only purchases (code P) and sales (code S) count; grants, option exercises and tax withholding do not.
Who was the last insider to trade VIVS on the open market?
Tony Serge Lialin (Chief Commercial Officer) bought $2,804 of VIVS on Aug 31, 2026 and filed the Form 4 on Sep 1, 2026. InsiderTell scored 23 (weak).
How many insiders file Form 4 at VivoSim Labs, INC.?
7 people have filed a Form 4 at VivoSim Labs, INC., among them Douglas Jay Cohen (director), David Gobel (director), Tony Serge Lialin (Chief Commercial Officer). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.